CN107540709A - The application of tizoxanide phosphate and alkyl sulfonic ester in terms of zika virus infection is treated - Google Patents

Abstract

The present invention relates to the tizoxanide phosphate shown in Formulas I or alkyl sulfonates compound, its officinal salt, its isomers, its hydrate or its solvate, and the pharmaceutical composition containing this compound, for treating zika virus infection.

Description

Tizoxanide phosphate and alkyl sulfonic ester are in terms of zika virus infection is treated Using

Technical field

The present invention relates to Formulas I tizoxanide phosphate or alkyl sulfonates compound and its officinal salt, its isomers, Its hydrate or its solvate, and the pharmaceutical composition containing above-claimed cpd, for treating zika virus infection in terms of use On the way.

Background technology

Formulas I tizoxanide phosphate or alkyl sulfonates compound are Poison ＆ Medicine Inst. of Military Medicial Sciences Academy's pins For Nitazoxanide (Formula II compound) bioavilability is low, half-life short, blood concentration are low and the Nitazoxanide of innovation and creation Prodrug, can rapid conversion activity form tizoxanide (formula III compound) in vivo, having improves cylinder therapeutic effect , high bioavilability, effective blood drug concentration hold time long, the more stable new construction type chemical combination of plasma concentration curve Thing.

Nitazoxanide is studied initially as a kind of oral anti-parasite medicine, in vitro and in different animal models Good antiprotozoal activity is respectively provided with, its clinical research first is treatment human intestine tapeworm.Subsequent external and In vivo study It was found that it has good inhibition to new hair protozoon and Cryptosporidium.1998, U.S. FDA approval Nitazoxanide be used as into People and the clinical treatment medicine of one-year-old above childhood infection Cryptosporidum parvum and giardia lamblia stiles.2006, clinical research card Real Nitazoxanide can effectively treat children's diarrhae caused by rotavirus infection.In addition, Nitazoxanide is also proved to adult Viral gastroenteritis and hepatitis C have good clinical therapeutic efficacy (Rossignol JF, Nitazoxanide：a First-in-class broad-spectrum antiviral agent, Antiviral Res.2014；110：94- 103.)。

In recent years number of lab research confirm, Nitazoxanide can upon translation the stage block influenza virus hemagglutinin egg White maturation, efficient inhibitory activity is respectively provided with to Flu-A, influenza B.Clinical study results show, twice a day, every time 600mg, it is continuous take 5 days Nitazoxanides can effectively reduce common influenza the course of disease (Haffizulla J, Hartman A, Hoppers M, et al, Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza：A double-blind, randomised, placebo-controlled, phase 2b/3trial, Lancet Infect Dis.2014；14(7)：609-18.).

Zika virus disease common symptoms are low-heat, plaque-like papule, headache, arthralgia, myalgia, powerless and apyetous Conjunctivitis.Human body was fallen ill by usual two to seven days after mosquito bite, and the incidence of disease is about 1/5th.The infected's clinical symptoms are failed to understand It is aobvious, typically last for several days to one week.Severe cases need to be hospitalized for treatment, rare death (Lucey, D.R.et al；Zika Virus infection, Pan American Health Organization/World Health Organization). Extensive zika virus epidemic situation is broken out in May, 2015, Brazil.In this epidemic situation, people have found zika virus and new life first Youngster's microcephaly and other embryo's development of central nervous system are extremely related, and the virus progressively turns into International Medical study hotspot. The primary vehicle of zika virus is Aedes aegypti, but increasing research shows that zika virus is not only in saliva, urine Deng can be detected in body fluid, and can long-term existence in semen.At present it has proven convenient that zika virus can pass man, man by man Woman's sexual transmission is passed to be propagated.Clinical studies show, pregnant woman infect stockaded village's card in three months or so in pregnancy, may influence embryo Tire nervous system development, cause miscarriage, neonate's microcephaly and other neonate's nervous system development abnormal diseases.At present, For zika virus infection based on supportive treatment of suiting the medicine to the illness, it can use without special antiviral drugs.On stockaded village of China, card input risk adds Under acute background, the research and development for accelerating anti-zika virus medicine are significant to China.

The content of the invention

The present invention seeks to find the medicine for having antiviral activity to zika virus, available for rescuing for zika virus infection Control.The present invention has found formula (I) tizoxanide phosphate or alkyl sulfonates compound by the research of creativeness, has protection The cell of zika virus infection, suppresses the function in terms of zika virus duplication, has in terms of zika virus disease is treated good Effect.

The present invention, which provides, has Formulas I tizoxanide phosphate or alkyl sulfonates compound,

Wherein：X=P or S,

As X=P,Singly-bound is represented, R1, R2 are each independently selected from hydroxyl, C1-6 alkoxies, aryl and substituted C1-6 alkoxies, described C1-6 alkoxies or aryl are optionally independently selected from following substituent by 1-2 and substituted：Amino, hydroxyl Base, cyano group, nitro, C1-4 alkyl, halogen (such as fluorine, chlorine, bromine or iodine)；

As X=S,Double bond is represented, R1 O, R2 are C1-6 alkyl, aryl, and described C1-6 alkyl or aryls are appointed Choosing is independently selected from following substituent by 1-2 and substituted：Amino, hydroxyl, cyano group, nitro, C1-4 alkyl, halogen (such as fluorine, Chlorine, bromine or iodine), tertbutyloxycarbonyl.

In one embodiment, the compound of formula I described in any one of first aspect present invention, its officinal salt, its is different Structure body, its hydrate or its solvate, wherein,

As X=P,Singly-bound is represented, R1, R2 are each independently selected from hydroxyl, C1-4 alkoxies, phenyl and substituted C1-4 alkoxies, described C1-4 alkoxies or aryl are optionally independently selected from following substituent by 1-2 and substituted：Amino, hydroxyl Base, cyano group, nitro, C1-4 alkyl, halogen (such as fluorine, chlorine, bromine or iodine)；

As X=S,Double bond is represented, R1 O, R2 are C1-4 alkyl, phenyl, and described C1-4 alkyl or phenyls are appointed Choosing is independently selected from following substituent by 1-2 and substituted：Amino, hydroxyl, cyano group, nitro, C1-4 alkyl, halogen (such as fluorine, Chlorine, bromine or iodine), tertbutyloxycarbonyl.

In another embodiment, the compound of formula I described in any one of first aspect present invention, its officinal salt, its Isomers, its hydrate or its solvate, wherein,

As X=P,Singly-bound is represented, R1, R2 are each independently selected from hydroxyl, methoxyl group, ethyoxyl, n-propyl oxygen Base, isopropyl epoxide, normal-butyl epoxide, sec-butyl epoxide, isobutyl group epoxide, tert-butyl group epoxide, benzyl epoxide, phenyl ethoxy Base, 1- phenyl-propoxies, 1- phenylbutoxies, fluoro-methoxy, difluoro-methoxy, trifluoromethoxy, chloromethoxy, dichloro Methoxyl group, trichloromethyl base, aminomethoxy, amino ethoxy, hydroxymethoxy, hydroxyl-oxethyl, nitromethoxy, nitro Ethyoxyl；

As X=S,Double bond is represented, R1 O, R2 are methyl, ethyl, n-propyl, isopropyl, normal-butyl, Zhong Ding Base, isobutyl group, the tert-butyl group, phenyl, methyl fluoride, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, to first Base phenyl, an aminomethyl phenyl, o-methyl-phenyl, amino methyl, amino-ethyl, hydroxymethyl, hydroxymethyl, nitromethyla, nitre Base ethyl, tertbutyloxycarbonyl methyl, tertbutyloxycarbonyl ethyl.

In another embodiment, the compound of formula I described in first aspect present invention, its officinal salt, its isomers, Its hydrate or its solvate, wherein,

As X=P, described salt is the addition salts that compound of formula I is formed with suitable alkali；

As X=S, described salt is the addition salts that compound of formula I is formed with suitable acid.

In another embodiment, the compound of formula I described in any one of first aspect present invention, its officinal salt, its Isomers, its hydrate or its solvate, it is selected from：

Compound 1：Dibenzyl 2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester；

Compound 2：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester；

Compound 3：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester mono-sodium salt；

Compound 4：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester disodium salt；

Compound 5：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester calcium salt；

Compound 6：2- (5- nitrothiazole -2- bases carbamoyl) phenyl methyl sulphonic acid ester；

Compound 7：2- (5- nitrothiazole -2- bases carbamoyl) phenylethyl sulphonic acid ester；

Compound 8：2- (5- nitrothiazole -2- bases carbamoyl) phenyl 1- propyl sulfonic acid esters；

Compound 9：2- (5- nitrothiazole -2- bases carbamoyl) phenyl 1- butyl sulfonic acid esters；

Compound 10：2- (5- nitrothiazole -2- bases carbamoyl) phenyl p-methylphenyl sulphonic acid ester；

Compound 11：2- (5- nitrothiazole -2- bases carbamoyl) phenyl [N-BOC- taurine esters；

Compound 12：2- (5- nitrothiazole -2- bases carbamoyl) phenyl taurine ester hydrochloride；

Compound 13：2- (5- nitrothiazole -2- bases carbamoyl) phenyl taurine ester

Compound 14：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester monopotassium salt；

Compound 15：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester di-potassium；

Compound 16：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester meglumine salt；

Compound 17：Dimethyl 2- (5- nitrothiazole -2- bases carbamoyl) phenyl phosphate ester；

Compound 18：Diethyl 2- (5- nitrothiazole -2- bases carbamoyl) phenyl phosphate ester.

The second aspect of the present invention is related to a kind of pharmaceutical composition, and it includes the formula described in any one of first aspect present invention I, its officinal salt, its hydrate or its solvate.

In a preferred embodiment, the pharmaceutical composition described in second aspect of the present invention, it is also comprising pharmaceutically Acceptable carrier or auxiliary material.Solid pharmaceutical preparation, injection, external preparation, spray can be made as needed for described pharmaceutical composition Agent, liquid preparation or compound preparation.

According to the present invention, formula (I) compound can protect cytopathic effect (CPE) of the cell caused by virus infects, And the suppressing virus replication on cell, reduce viral nucleic acid carrying capacity in cell culture.

The present inventor is after substantial amounts of research, it was found that some new works of formula (I) compound in the cell Use feature：

First, formula (I) compound in Antiviral breeding, can reduce zika virus sense under micromolar concentrations in vitro The cell CPE of dye is horizontal；

Second, the cell virus nucleic acid that formula (I) compound can reduce zika virus infection under micromolar concentrations carries Amount is horizontal；

The invention further relates to containing formula (I) compound and its pharmaceutically acceptable salt and/or its is pharmaceutically acceptable Solvate or the pharmaceutical composition of its hydrate and pharmaceutically acceptable carrier.The officinal salt of the compounds of this invention includes Its inorganic or acylate, and inorganic or organic alkali salt, the present invention relates to the form of ownership of above-mentioned salt.Including but it is unlimited In：Sodium salt, sylvite, calcium salt, lithium salts, meglumine salt, hydrochloride, hydrogen Australia hydrochlorate, the sumptuous hydrochlorate of hydrogen, nitrate, sulfate, hydrogen sulfate Salt, phosphate, hydrophosphate, acetate, propionate, butyrate, oxalates, pivalate, adipate, alginates, Lactate, citrate, tartrate, succinate, maleate, fumarate, picrate, aspartate, glucose Hydrochlorate, benzoate, mesylate, esilate, benzene sulfonate, tosilate and embonate etc..

The pharmaceutical composition can be applied through number of ways, such as oral tablet, capsule, pulvis, oral liquid, injection and Preparation capable of permeating skin.According to the convention on the medicine of routine, pharmaceutically acceptable carrier includes diluent, filler, disintegrant, profit Humectant, lubricant, colouring agent, flavor enhancement or other conventional additives.Typical pharmaceutically acceptable carrier includes for example micro- Crystalline cellulose, starch, commissure PVP, PVP, polyvinylpyrrolidone, maltitol, citric acid, dodecyl sodium sulfate Or magnesium stearate etc..

Another aspect of the present invention is related to pharmaceutical composition, and it, which contains the compounds of this invention at least one, can pharmaceutically connect The carrier received.Described pharmaceutical composition can be prepared into various forms according to different way of administration.

Brief description of the drawings

Fig. 1 tizoxanides and Nitazoxanide effectively protect the vero cells CPE that zika virus infects.(a) Nitazoxanide exists Under various concentrations, effectively protection, and between inhibiting rate and dosage can be produced to the CPE after zika virus infection cell With dose-effect relationship.(b) tizoxanide can produce effective under various concentrations to the CPE after zika virus infection cell Protection, and there is dose-effect relationship between inhibiting rate and dosage.

Fig. 2 tizoxanides and Nitazoxanide effectively reduce viral nucleic acid carrying capacity in the vero cells that zika virus infects. (a) virus load during Nitazoxanide and tizoxanide can suppress cell after cell infection zika virus 80h, wherein 10 μM Drug concentration can completely inhibit propagation of the virus in cell.(b) 10 μM of Nitazoxanide different time after cell infection Detection, the inhibitory activity to virus can be observed.(c) 10 μM of tizoxanide different time after cell infection detects, The inhibitory activity to virus can be observed.(d) Nitazoxanide of various concentrations and tizoxanide are individually to subject cell processing 80h, cytotoxicity is not observed.

Embodiment

The following examples are the illustrative preferred embodiments of the present invention, and the present invention is not limited in any way.

Embodiment 1：Nitazoxanide and reduce zika virus infection cell CPE experiment for azoles Buddhist nun

The experiment material and experimental method used in the present invention：

(1) cell culture and cell line

African green monkey kidney cell (Vero) used preserves for this room in experimentation, and source and passage number are clear and definite.Cell 37 DEG C are incubated at, 5%CO₂Moisture-saturated cell culture incubator in.Generally passed on by 1: 3-1: 6, liquid is changed per 48h in incubation Once, about 2-5 days (cell confluent monolayers) are passed on 0.25% EDTA pancreatin digestion 2min.Used in cell growth completely The DMEM high glucose mediums that culture medium is addition 10%FBS and mycillin is dual anti-, culture medium is maintained as addition 2%FBS and green grass or young crops The dual anti-DMEM high glucose mediums of streptomysin.

(2) cell viability detects

Cell viability is usedLuminescent Cell Viability Assay are determined.It is paved with bottom of bottle Vero cells be resuspended after the digestion of 0.25%EDTA pancreatin with complete medium, single cell suspension is prepared, with every hole after counting The density of 10000 cells is inoculated with 96 orifice plates, in 37 DEG C, the 5%CO of moisture-saturated₂Under the conditions of cultivate 24 hours.Cultivated with maintenance Base dilutes ZIKA virus stock solution useds, adds 96 orifice plates, makes its final concentration of 100TCID50；Meanwhile by Nitazoxanide and tizoxanide With maintaining culture medium doubling dilution to add 96 orifice plates, its final concentration is respectively 10 μM, 3.3 μM, 1.1 μM, 0.3 μM, 0.1 μM, 0.03 μM, 0.01 μM and 0.003 μM, cell controls group and virus control group are set.Supernatant is abandoned after processing 80h, adds and uses per hole 2 times of dilutions of PBSLuminescent Cell Viability detect liquid, lucifuge concussion cracking 5min, 3min is stood, finally determine fluorescence signal intensity with Molecular Devices M5 ELIASAs.Medicament protection cell CPE inhibiting rate calculation formula is：

Embodiment 2：Nitazoxanide and tizoxanide reduce the cell virus nucleic acid load experiment of zika virus infection

(1) drug-treated

With 2% cell maintenance medium by ZIKA viral dilutions into respective concentration, then adding in 6 orifice plates makes every hole contain virus Measure as 100TCID50, then Nitazoxanide and tizoxanide are diluted to respective concentration respectively with 2% cell maintenance medium, be added to In corresponding hole, it is respectively 10 μM, 1 μM and 0.1 μM to make medicine ultimate density, then put 37 DEG C, 5%CO2 incubators be incubated it is 2 small When, nutrient solution is abandoned, the cell maintenance mediums of 2ml 2% are added per hole and continue to cultivate different time h, cell controls group only adds 2% cell Maintaining liquid.

(2) RNA is extracted

1) 350 μ L Buffer RLT are added in plate per hole, is mixed after it is fully cracked, is transferred to liquid-transfering gun pressure-vaccum In nuclease free EP pipes, centrifuging and taking supernatant；

2) 70% isometric ethanol is added, is mixed；

3) above-mentioned mixed liquor is transferred in the centrifugal column of no RNase, 12000rpm centrifugation 15s, abandons waste liquid；

4) 700 μ L Buffer RW1,12000rpm centrifugation 15s are added, abandon waste liquid；

5) 500 μ L Buffer RPE, 12000rpm centrifugation 15s are added, abandon waste liquid；

6) 500 μ L Buffer RPE, 12000rpm centrifugation 2min are added, abandon waste liquid；

7) the 2ml collecting pipes without RNase renewed, 12000rpm centrifugation 1min, dry filter column；

8) new 1.5ml collecting pipes are changed, often pipe adds the water that 50 μ l are free of RNase, 12000rpm centrifugation 2min, elution Liquid contains corresponding RNA, adds RNase inhibitor, and each RNA concentration is detected with Nano Drop.

(3) RNA reverse transcriptions

Reverse transcription reagent box (the PrimeScript that experiment is produced using TaKaRa companies^TM RT reagent Kit with GDNA Eraser, article No. RR047Q) RNA reverse transcriptions are carried out, step is as follows.

1. gDNA is removed：Each experimental group RNA sample is collected, takes 1 μ g to carry out reverse transcription respectively.First, to each experimental group RNA 2 μ l 5 × gDNA Eraser Buffer of middle addition, reaction system is supplied to 10 μ l with RNase Free water, is fully mixed, 42 DEG C water-bath 2min removes g DNA that may be present in sample；

2. reverse transcription：Appropriate enzyme and primer Mix and reaction buffer are added into 1. gained sample, with RNase Free Water supplies volume to 20 μ l, 37 DEG C of water-bath 15min, and 5sec in 85 DEG C of water of input, both transcribed to obtain cDNA afterwards.

(4)Real-time PCR

Real-time PCR are carried out using the real-time quantitative PCR kit (article No. RR820Q) of TaKaRa companies production, step It is rapid as follows：

1. adjust added cDNA concentration in PCR courses of reaction by reference gene of β-actin：CDNA obtained by step (3) is taken, It is respectively stoste, 10 times of dilutions, 20 times of dilutions, 50 times of dilutions and 100 times of dilutions to set series concentration gradient, is added It is anti-that 10 μ l 2 × SYBR Premix Ex Taq II and β-actin primers (reaction system is 20 μ l) carry out Real-time PCR Should, amplification condition is：40 circulations, 95 DEG C of 10s, 60 DEG C of 30s, take cDNA concentration of the Cp values between 15-16 subsequently to be grasped Make；

After 2. cDNA dosages determine, ZIKARNA carrying capacity in sample is detected, condition is same as above, with 2 after the completion of experiment^-ΔΔCTMethod meter Calculate cell conditioned medium viral nucleic acid carrying capacity.The primer sequence is following in experimentation (being that 5 ' -3 ' directions represent)：

ZIKV-ASF：GGTCAGCGTCCTCTCTAATAAACG

ZIKV-ASR：GCACCCTAGTGTCCACTTTTTCC

β-actin-F：TGTCCACCTTCCAGCAGATGT

β-actin-R：AGCTCAGTAACAGTCCGCCTAGA

(3) compound on intracellular toxotest

The cytotoxicity of compound utilizesLuminescent Cell Viability Assay are surveyed It is fixed.The Vero cells for being paved with bottom of bottle are resuspended after the digestion of 0.25%EDTA pancreatin with complete medium, are prepared single cell suspension, are counted 96 orifice plates are inoculated with the density of every cell of hole 10000 after number, in 37 DEG C, the 5%CO of moisture-saturated₂Under the conditions of cultivate 24 hours. By Nitazoxanide and tizoxanide with maintaining culture medium doubling dilution to add 96 orifice plates, its final concentration is respectively 100 μM, 50 μM, 30 μM, 10 μM, 1 μM, 0.1 μM, cell controls group is set.Supernatant is abandoned after processing 80h, is added per hole with 2 times of dilutions of PBS 'sLuminescent Cell Viability detect liquid, lucifuge concussion cracking 5min, stand 3min, most Afterwards with Molecular Devices M5 measure fluorescence signal intensities.

Claims (6)

1. compound shown in Formulas I, its officinal salt, its isomers, its hydrate or its solvate,

Wherein：X=P or S,

As X=P,Singly-bound is represented, R1, R2 are each independently selected from hydroxyl, C1-6 alkoxies, the C1-6 alkane of aryl substitution Epoxide, described C1-6 alkoxies or aryl are optionally independently selected from following substituent by 1-2 and substituted：Amino, hydroxyl, cyanogen Base, nitro, C1-4 alkyl, halogen (such as fluorine, chlorine, bromine or iodine)；

As X=S,Double bond is represented, R1 O, R2 are C1-6 alkyl, aryl, described C1-6 alkyl or aryls optionally quilt 1-2 are independently selected from following substituent substitution：Amino, hydroxyl, cyano group, nitro, C1-4 alkyl, halogen (such as fluorine, chlorine, bromine Or iodine), tertbutyloxycarbonyl.

2. compound, its officinal salt, its isomers, its hydrate or its solvate described in claim 1, wherein,

As X=P, described salt is the addition salts that compound of formula I and alkali are formed, such as mono-sodium salt, double sodium salt, calcium salt, single potassium Salt, double sylvite, meglumine salt；

As X=S, described salt is the addition salts that compound of formula I is formed with acid, such as hydrochloride, sulfate, acetate, nitre Hydrochlorate.

3. compound, its officinal salt, its isomers, its hydrate or its solvate described in claim any one of 1-2, It is selected from：

Compound 1：Dibenzyl 2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester；

Compound 2：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester；

Compound 3：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester mono-sodium salt；

Compound 4：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester disodium salt；

Compound 5：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester calcium salt；

Compound 6：2- (5- nitrothiazole -2- bases carbamoyl) phenyl methyl sulphonic acid ester；

Compound 7：2- (5- nitrothiazole -2- bases carbamoyl) phenylethyl sulphonic acid ester；

Compound 8：2- (5- nitrothiazole -2- bases carbamoyl) phenyl 1- propyl sulfonic acid esters；

Compound 9：2- (5- nitrothiazole -2- bases carbamoyl) phenyl 1- butyl sulfonic acid esters；

Compound 10：2- (5- nitrothiazole -2- bases carbamoyl) phenyl p-methylphenyl sulphonic acid ester；

Compound 11：2- (5- nitrothiazole -2- bases carbamoyl) phenyl [N-BOC- taurine esters；

Compound 12：2- (5- nitrothiazole -2- bases carbamoyl) phenyl taurine ester hydrochloride；

Compound 13：2- (5- nitrothiazole -2- bases carbamoyl) phenyl taurine ester

Compound 14：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester monopotassium salt；

Compound 15：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester di-potassium；

Compound 16：2- (5- nitrothiazole -2- bases carbamoyl) phenyl dihydrogen phosphoric acid ester meglumine salt；

Compound 17：Dimethyl 2- (5- nitrothiazole -2- bases carbamoyl) phenyl phosphate ester；

Compound 18：Diethyl 2- (5- nitrothiazole -2- bases carbamoyl) phenyl phosphate ester.

4. a kind of pharmaceutical composition, its include compound of formula I any one of claims 1 to 3, its officinal salt, its Isomers, its hydrate or solvate,

Preferably, described pharmaceutical composition also includes pharmaceutically acceptable carrier or auxiliary material, specifically, the drug regimen Thing is solid pharmaceutical preparation, injection, external preparation, spray, liquid preparation or compound preparation.

5. compound of formula I, its officinal salt any one of the pharmaceutical composition or claims 1 to 3 of claim 4, Its isomers, its hydrate or solvate are preparing disease of viral infection caused by zika virus (such as microcephaly, neonate Nervous system development abnormal diseases) medicine in purposes.

6. one kind treatment and/or prophylactic method or in mammal in need in mammal in need Suppress the method for zika virus, this method includes the right that treatment and/or prevention effective dose are applied to mammal in need It is required that compound of formula I, its officinal salt, its isomers any one of 4 pharmaceutical composition or claims 1 to 3, its Hydrate or solvate, wherein described disease includes disease of viral infection caused by zika virus.